Xin Lang Cai Jing·2025-06-05 11:22Core Viewpoint - The article discusses the controversy surrounding Kelun Pharmaceutical's new product, Ergothioneine capsules, which has been labeled as a "fake drug" by a prominent biologist, leading to a significant drop in the stock prices of both Kelun Pharmaceutical and its subsidiary, Chuaning Biological. Company Summary - Kelun Pharmaceutical's chairman, Liu Gexin, promoted Ergothioneine capsules, resulting in a stock price increase of 16.75% for Kelun and 12.22% for Chuaning Biological over the past month [1][3] - Following the criticism from biologist Rao Yi, both companies experienced a stock price decline of 4.96% and 1.98%, respectively, closing at 37.75 CNY per share and 12.87 CNY per share, with market capitalizations of 603.27 billion CNY and 287.01 billion CNY [5] - Ergothioneine is a natural antioxidant derived from microorganisms, particularly edible mushrooms, and has been associated with various health benefits [5][6] Industry Summary - The product Ergothioneine has not yet been approved as a health supplement in China, and there are no registered products containing Ergothioneine found in the National Medical Products Administration's database [6][9] - The product is currently being sold in China through cross-border e-commerce after being exported to Japan for production, as it has not received domestic approval [6] - Ergothioneine's potential for oral consumption remains uncertain, as it is primarily used as a bioactive ingredient in cosmetic formulations [6]